Search

Recommendation for hematologists in COVID-19 crisis

Recommendations for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in patients with active cancer. It should be taken seriously and managed rigorously without jeopardizing the curative chance of individual cancer patients.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Meet Stefan Fröhling, our November volunteer of the month

Can you tell us what you do for EHA and when you started?
I first learned about EHA in 2002 when I attended the 7th Congress of EHA in Florence.

Read more

Cancer Medicines Forum workshop April 5: a way forward for treatment optimization

The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

Access

Improving affordable and equal access to innovative therapies in hematology for patients across Europe is EHA’s overriding advocacy priority.

Read more